Literature DB >> 23328480

NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.

Wen Zhou1, Ye Yang, Jiliang Xia, He Wang, Mohamed E Salama, Wei Xiong, Hongwei Xu, Shashirekha Shetty, Tiehua Chen, Zhaoyang Zeng, Lei Shi, Maurizio Zangari, Rodney Miles, David Bearss, Guido Tricot, Fenghuang Zhan.   

Abstract

Using sequential gene expression profiling (GEP) samples, we defined a major functional group related to drug resistance that contains chromosomal instability (CIN) genes. One CIN gene in particular, NEK2, was highly correlated with drug resistance, rapid relapse, and poor outcome in multiple cancers. Overexpressing NEK2 in cancer cells resulted in enhanced CIN, cell proliferation and drug resistance, while targeting NEK2 by NEK2 shRNA overcame cancer cell drug resistance and induced apoptosis in vitro and in a xenograft myeloma mouse model. High expression of NEK2 induced drug resistance mainly through activation of the efflux pumps. Thus, NEK2 represents a strong predictor for drug resistance and poor prognosis in cancer and could be an important target for cancer therapy.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328480      PMCID: PMC3954609          DOI: 10.1016/j.ccr.2012.12.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  47 in total

1.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.

Authors:  Margaret A Shipp; Ken N Ross; Pablo Tamayo; Andrew P Weng; Jeffery L Kutok; Ricardo C T Aguiar; Michelle Gaasenbeek; Michael Angelo; Michael Reich; Geraldine S Pinkus; Tane S Ray; Margaret A Koval; Kim W Last; Andrew Norton; T Andrew Lister; Jill Mesirov; Donna S Neuberg; Eric S Lander; Jon C Aster; Todd R Golub
Journal:  Nat Med       Date:  2002-01       Impact factor: 53.440

2.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

3.  Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.

Authors:  Dirk Hose; Thierry Rème; Thomas Hielscher; Jérôme Moreaux; Tobias Messner; Anja Seckinger; Axel Benner; John D Shaughnessy; Bart Barlogie; Yiming Zhou; Jens Hillengass; Uta Bertsch; Kai Neben; Thomas Möhler; Jean François Rossi; Anna Jauch; Bernard Klein; Hartmut Goldschmidt
Journal:  Haematologica       Date:  2010-09-30       Impact factor: 9.941

4.  Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations.

Authors:  M J Calasanz; J C Cigudosa; M D Odero; C Ferreira; M T Ardanaz; A Fraile; J L Carrasco; F Solé; B Cuesta; A Gullón
Journal:  Genes Chromosomes Cancer       Date:  1997-02       Impact factor: 5.006

Review 5.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

6.  Phosphorylation of Bax Ser184 by Akt regulates its activity and apoptosis in neutrophils.

Authors:  Shyra J Gardai; David A Hildeman; Steve K Frankel; Ben B Whitlock; S Courtney Frasch; Niels Borregaard; Philippa Marrack; Donna L Bratton; Peter M Henson
Journal:  J Biol Chem       Date:  2004-02-06       Impact factor: 5.157

7.  Nip2/centrobin may be a substrate of Nek2 that is required for proper spindle assembly during mitosis in early mouse embryos.

Authors:  Seongkeun Sonn; Yeontae Jeong; Kunsoo Rhee
Journal:  Mol Reprod Dev       Date:  2009-06       Impact factor: 2.609

8.  Phosphorylation of human Sgo1 by NEK2A is essential for chromosome congression in mitosis.

Authors:  Guosheng Fu; Xia Ding; Kai Yuan; Felix Aikhionbare; Jianhui Yao; Xin Cai; Kai Jiang; Xuebiao Yao
Journal:  Cell Res       Date:  2007-07       Impact factor: 25.617

9.  Targeting the WNT/beta-catenin/TCF/LEF1 axis in solid and haematological cancers: Multiplicity of therapeutic options.

Authors:  Iris Gehrke; Rajesh Kumar Gandhirajan; Karl-Anton Kreuzer
Journal:  Eur J Cancer       Date:  2009-09-02       Impact factor: 9.162

Review 10.  Original CIN: reviewing roles for APC in chromosome instability.

Authors:  Nasser M Rusan; Mark Peifer
Journal:  J Cell Biol       Date:  2008-06-02       Impact factor: 10.539

View more
  133 in total

1.  Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.

Authors:  Gang An; Yan Xu; Lihui Shi; Zhong Shizhen; Shuhui Deng; Zhenqing Xie; Weiwei Sui; Fenghuang Zhan; Lugui Qiu
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

2.  Effect of HM910, a novel camptothecin derivative, on the inhibition of multiple myeloma cell growth in vitro and in vivo.

Authors:  Juan Li; Yudan Ouyang; Xu Zhang; Wenqiang Zhou; Fang Wang; Zhencong Huang; Xiaokun Wang; Yifan Chen; Hui Zhang; Liwu Fu
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

3.  A subset of CD20(+) MM patients without the t(11;14) are associated with poor prognosis and a link to aberrant expression of Wnt signaling.

Authors:  Jing Liu; Zhimin Gu; Ye Yang; Erik Wendlandt; Hongwei Xu
Journal:  Hematol Oncol       Date:  2014-01-09       Impact factor: 5.271

4.  Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.

Authors:  Jia Wang; Peng Cheng; Marat S Pavlyukov; Hai Yu; Zhuo Zhang; Sung-Hak Kim; Mutsuko Minata; Ahmed Mohyeldin; Wanfu Xie; Dongquan Chen; Violaine Goidts; Brendan Frett; Wenhao Hu; Hongyu Li; Yong Jae Shin; Yeri Lee; Do-Hyun Nam; Harley I Kornblum; Maode Wang; Ichiro Nakano
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

5.  The X-linked deubiquitinase USP9X is an integral component of centrosome.

Authors:  Qian Wang; Yiman Tang; Yue Xu; Shilei Xu; Yong Jiang; Qiuping Dong; Yongsheng Zhou; Wenshu Ge
Journal:  J Biol Chem       Date:  2017-06-15       Impact factor: 5.157

Review 6.  Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.

Authors:  Yusuke Furukawa; Jiro Kikuchi
Journal:  Int J Hematol       Date:  2016-07-13       Impact factor: 2.490

7.  Cancerous inhibitor of protein phosphatase 2A (CIP2A) protein is involved in centrosome separation through the regulation of NIMA (never in mitosis gene A)-related kinase 2 (NEK2) protein activity.

Authors:  Ae Lee Jeong; Sunyi Lee; Jeong Su Park; Sora Han; Chang-Young Jang; Jong-Seok Lim; Myung Sok Lee; Young Yang
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

Review 8.  Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis.

Authors:  J Jeffery; D Sinha; S Srihari; M Kalimutho; K K Khanna
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  High expression of NEK2 promotes gastric cancer progression via activating AKT signaling.

Authors:  Hao Wan; Lin Xu; Huangbin Zhang; Feixiang Wu; Weiqiang Zeng; Taiyuan Li
Journal:  J Physiol Biochem       Date:  2020-11-17       Impact factor: 4.158

10.  Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.

Authors:  Zhen Ning; Aman Wang; Jinxiao Liang; Jiwei Liu; Tao Zhou; Qiu Yan; Zhongyu Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.